MiRus
Medical device maker turning molybdenum-rhenium alloy into spine implants and a new heart valve.
On the record
Checkpoint: STAR pivotal trial interim readout and FDA review milestones for the SIEGEL TAVR valve
The call
MiRus's spine business is small and steady, but almost all of its $4.4B value rides on an unapproved heart valve still in trial against two entrenched rivals.
MiRus makes special materials and a new heart valve called SIEGEL TAVR designed to replace failing heart valves without surgery. The company has real patents and FDA attention, but almost the entire $4.4 billion value depends on whether SIEGEL TAVR actually works in its ongoing trial and gets approved. Two giants, Edwards and Medtronic, already own the heart valve market with proven products, and even Boston Scientific (which has an option to buy the SIEGEL TAVR business separately for $3 billion) has tried and failed twice before to break in here. The one thing that changes everything: whether the SIEGEL trial succeeds in the next year or two, and whether Boston Scientific actually pulls the trigger to buy it.
Why
01
AI pressure: None apparent. This is a metallurgy and cardiac device business; AI models don't build heart valves or spine hardware. Could AI do the core job? Unlikely.
02
Bigger players: Edwards Lifesciences (Sapien) and Medtronic (Evolut). Sapien and Evolut already hold the TAVR market; MiRus's SIEGEL valve is still investigational, unapproved, and unproven against them. Could a giant copy it? Probably.
03
What protects it. 139 patents on its molybdenum-rhenium alloy, FDA Breakthrough status, CMS payment approval, and Boston Scientific's $1.5B stake and $3B buyout option tying its fate to the trial's outcome.
What would change this call
STAR trial interim readout or enrollment update reported through 2027-2028. Shows whether SIEGEL TAVR is on track for FDA approval or facing delay/safety issues.
Boston Scientific exercises or declines its $3B option to acquire the TAVR business. Reveals whether BSX sees the valve as a validated near-term commercial winner.
FDA approval decision date announced for SIEGEL TAVR. Determines whether MiRus can actually enter the market Edwards and Medtronic control.
Boston Scientific exercises or declines its $3B option to acquire the TAVR business. Reveals whether BSX sees the valve as a validated near-term commercial winner.
FDA approval decision date announced for SIEGEL TAVR. Determines whether MiRus can actually enter the market Edwards and Medtronic control.
Key numbers
- Boston Scientific paid $1.5B for a 34% stake
- Boston Scientific holds a $3B option to buy the TAVR unit
- STAR trial enrolling up to 1,025 patients
Named risks
- SIEGEL TAVR's STAR pivotal trial could show non-inferiority miss or adverse events vs Sapien/Evolut.
- SIEGEL remains investigational and unapproved as of 2026-05-18, so FDA delay or rejection is possible.
- Boston Scientific could decline to exercise its $3B option, capping equity holder upside.
- Legacy spine implant business faces crowded incumbent competition and reported deprioritization.
- Publicly available revenue and headcount figures are inconsistent third-party estimates, not company-disclosed.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Edwards Lifesciences | contesting | Sapien platform dominates TAVR market as of 2025-06-03, unaffected by SIEGEL's investigational status |
| Medtronic | contesting | Evolut/CoreValve leads TAVR and Medtronic countered by investing $90M in rival Anteris on 2026-05-18 |
| Boston Scientific | gaining on | Took 34% stake and $3B option on 2026-05-18, positioned to absorb MiRus's TAVR upside directly |
| Anteris Technologies | gaining on | Received $90M Medtronic strategic investment in similar structure, announced 2026-05-18 |
| Meril Life Sciences | gaining on | Myval TAVR valve already has published comparative LANDMARK trial data as of 2025-01-23 |
Questions people ask
- Is MiRus profitable?
- MiRus does not disclose audited financials as a private company. Its spine implant line generates modest sales, but its flagship SIEGEL TAVR valve is still investigational and unapproved by the FDA as of the May 18, 2026 Boston Scientific deal announcement, meaning no approved-product revenue exists yet.
- Who owns MiRus?
- MiRus is privately held, but on May 18, 2026, Boston Scientific announced a $1.5 billion investment for an approximately 34% equity stake, implying a roughly $4.4 billion post-money valuation and giving Boston Scientific board representation and governance rights.
- Could AI replace MiRus?
- No. MiRus's value rests on proprietary molybdenum-rhenium metallurgy, 139 filed patents as of June 15, 2026, and FDA/CMS regulatory clearances, none of which are software workflows AI can automate. Its only software layer, GALILEO RPM, is a minor add-on to hardware sales.
- Has MiRus's SIEGEL TAVR valve been approved by the FDA?
- No. As of the May 18, 2026 Boston Scientific investment announcement, SIEGEL remained investigational, with MiRus enrolling up to 1,025 patients in its STAR pivotal trial to seek eventual FDA approval.
- Who is MiRus's biggest competitor?
- In transcatheter aortic valve replacement, Edwards Lifesciences (Sapien) and Medtronic (Evolut/CoreValve) dominate the market as of June 3, 2025, while Boston Scientific itself is a re-entrant after two failed prior TAVR attempts, Acurate and Lotus Edge.
- What is MiRus's valuation?
- Boston Scientific's $1.5 billion investment for a 34% equity stake, announced May 18, 2026, implies an approximate $4.4 billion post-money valuation, derived by dividing the investment by the stake percentage rather than disclosed directly by either company.
Timeline
- 2026-06-23Trade press details SIEGEL's 8 Fr sheath, claimed ~50% smaller than rival TAVR systems
- 2026-05-18Boston Scientific invests $1.5B for ~34% stake in MiRus, gains $3B TAVR acquisition option
- 2026-04-08MiRus publicizes CMS New Technology Add-on Payment for EUROPA system
- 2025-08-01CMS grants New Technology Add-on Payment (NTAP) for EUROPA Posterior Cervical System
- 2024-07-31FDA grants Breakthrough Device Designation for EUROPA spine implant
- 2023-01-03MiRus announces $65 million raise for rhenium-based device expansion
Revision history
29 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Boston Scientific announces strategic investment in MiRus LLC (2026-05-18)
- Boston Scientific invests $1.5B in MiRus TAVR deal (2026-05-18)
- Boston Scientific Invests $1.5 Billion in Heart Valve Startup MiRus, Gains Option to Acquire TAVR Business (2026-05-18)
- How Spine's material distraction became a $4B Cardio materials play (2026-05)
- MiRus Receives Breakthrough Device Designation for Spine Implant (2024-08-13)
- MiRus Receives New Technology Add-on Payment (NTAP) for EUROPA™ Posterior Cervical Fusion System (2026-04-08)
- Products, Competitors, Financials, Employees, Headquarters Locations (2026-06-15)
- Why Boston Scientific bet $1.5B on MiRus' molybdenum-rhenium valve (2026-06-23)
- TAVR Market 2025: Growth, Innovation, and Competition (2025-06-03)
- Boston Scientific invests $1.5B in TAVR developer MiRus (2026-05-18)
- Early outcomes with Myval TAVR valve comparable to popular devices from Medtronic, Edwards (2025-01-23)
- MiRus® Raises $65 Million For Expansion of Rhenium-based Medical Devices (2023-01-03)